FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
PARIS and TARRYTOWN, NY– April 26, 2019– The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Attack | Stroke